SecSonar.com

Exelixis, Inc. (EXEL)

Exelixis, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Exelixis, Inc. (EXEL) is a Biotechnology company based in US with a market capitalization of $12.9B. Revenue grew 7.0% year-over-year and the company generated $844.3M in free cash flow. This page tracks EXEL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 1.15K employees · IPO Apr 17, 2000

Valuation

Valuation & price

$50.13 · as of May 17, 2026 · -10.2% vs 52w high

18.1

P/E ratio

Latest-FY diluted EPS

5.96

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$55.85$45.99$36.13Jul 25Dec 25Jul 26Jul 7, 25$44.16Jul 9, 25$44.07Jul 11, 25$44.86Jul 15, 25$44.06Jul 17, 25$44.87Jul 21, 25$44.26Jul 23, 25$45.40Jul 25, 25$45.60Jul 29, 25$36.94Jul 31, 25$36.22Aug 4, 25$36.81Aug 6, 25$37.71Aug 11, 25$37.41Aug 13, 25$38.49Aug 15, 25$38.31Aug 19, 25$37.52Aug 21, 25$38.71Aug 25, 25$37.90Aug 27, 25$38.51Aug 29, 25$37.42Sep 3, 25$36.96Sep 5, 25$37.88Sep 9, 25$38.28Sep 11, 25$39.07Sep 16, 25$39.14Sep 18, 25$40.45Sep 22, 25$39.58Sep 24, 25$38.91Sep 26, 25$39.04Sep 30, 25$41.30Oct 2, 25$41.35Oct 6, 25$40.01Oct 8, 25$38.64Oct 10, 25$38.15Oct 14, 25$39.51Oct 16, 25$39.21Oct 21, 25$36.13Oct 23, 25$38.05Oct 27, 25$39.99Oct 29, 25$39.43Oct 31, 25$38.67Nov 4, 25$37.90Nov 6, 25$40.80Nov 10, 25$41.41Nov 12, 25$43.59Nov 14, 25$41.65Nov 18, 25$42.65Nov 20, 25$41.78Nov 25, 25$43.13Nov 28, 25$44.17Dec 2, 25$43.44Dec 4, 25$44.37Dec 8, 25$42.17Dec 10, 25$41.07Dec 12, 25$40.88Dec 16, 25$41.60Dec 18, 25$42.57Dec 22, 25$46.19Dec 24, 25$46.51Dec 29, 25$45.37Jan 2, 26$43.58Jan 6, 26$43.68Jan 8, 26$44.15Jan 12, 26$44.06Jan 14, 26$45.23Jan 16, 26$43.96Jan 21, 26$44.81Jan 23, 26$44.27Jan 27, 26$43.74Jan 29, 26$42.28Feb 2, 26$42.81Feb 4, 26$42.65Feb 9, 26$43.95Feb 11, 26$42.94Feb 13, 26$43.92Feb 18, 26$44.47Feb 20, 26$43.63Feb 24, 26$45.14Feb 26, 26$44.28Mar 2, 26$41.03Mar 4, 26$41.69Mar 6, 26$41.55Mar 10, 26$41.29Mar 12, 26$41.17Mar 17, 26$41.83Mar 19, 26$41.26Mar 23, 26$41.41Mar 25, 26$42.79Mar 27, 26$41.53Mar 31, 26$42.89Apr 2, 26$43.88Apr 7, 26$43.99Apr 9, 26$45.41Apr 13, 26$44.96Apr 15, 26$44.28Apr 17, 26$44.89Apr 22, 26$46.85Apr 24, 26$44.94Apr 28, 26$44.93Apr 30, 26$44.46May 4, 26$44.17May 6, 26$48.70May 8, 26$48.16May 12, 26$49.46May 14, 26$51.10May 18, 26$49.84May 20, 26$49.90May 22, 26$50.15May 28, 26$51.45Jun 1, 26$50.28Jun 3, 26$51.60Jun 5, 26$52.70Jun 9, 26$52.99Jun 11, 26$53.50Jun 15, 26$53.00Jun 17, 26$52.44Jun 22, 26$51.35Jun 24, 26$52.87Jun 26, 26$54.77Jul 2, 26$55.85
$34.5452-week range$55.85
Loading valuation history…

Fundamentals

Key fundamentals

$12.9B

Market cap

7.0%

Revenue growth (YoY)

96.4%

Gross margin

$844.3M

Free cash flow (USD)

-$886.1M

Net debt

Net cash position

-6.4%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2026

FY 2016$191.5MFY 2017$452.5MFY 2018$853.8MFY 2019$967.8MFY 2020$987.5MFY 2021$1.4BFY 2022$1.6BFY 2023$1.8BFY 2025$2.2BFY 2026$2.3B
$191.5M$2.3B

Free cash flow by year

2016 → 2026

FY 2016$204.6MFY 2017$144.5MFY 2018$382.4MFY 2019$514.1MFY 2020$178.6MFY 2021$336.6MFY 2022$224.2MFY 2023$170.4MFY 2025$633.8MFY 2026$844.3M
$204.6M$844.3M

Gross margin by year

2021 → 2026

FY 202196.3%FY 202296.4%FY 202396.0%FY 202596.5%FY 202696.4%
96.3%96.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

9

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $492K · 10b5-1 PlanEckhardt Sue Gail · Director · $492KJun 3, 2026Filing
  • Insider sellInsider Sell $198K · 10b5-1 PlanWYSZOMIERSKI JACK L · Director · $198.4KJun 3, 2026Filing
  • 8-K eventEquity Incentive Plan AmendedMay 29, 2026Filing
  • Insider sellInsider Sell $2.2MAftab Dana · EVP, Research and Development · $2.2MMay 28, 2026Filing
  • Insider sellInsider Sell $1.6MHaley Patrick J. · EVP, Commercial · $1.6MMay 22, 2026Filing
  • Insider sellInsider Sell $333K · 10b5-1 PlanHefti Brenda · SVP and General Counsel · $332.6KMay 19, 2026Filing
  • Insider sellInsider Sell $1.7MSenner Christopher J. · EVP and CFO · $1.7MMay 19, 2026Filing
  • Insider sellInsider Sell $2.7MPOSTE GEORGE · Director · $2.7MMay 8, 2026Filing
  • Insider sellInsider Sell $949KFreire Maria C · Director · $949.2KMay 8, 2026Filing
  • Insider sellInsider Sell $374KBeckerle Mary C · Director · $373.6KMay 8, 2026Filing

Questions

Frequently asked questions

What is Exelixis, Inc.'s market cap?

Exelixis, Inc. (EXEL) has a market capitalization of $12.9B.

What is EXEL's P/E ratio?

EXEL trades at a price-to-earnings ratio of 18.1, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is EXEL's price-to-book (P/B) ratio?

EXEL trades at 5.96 times book value per share.

Are insiders buying EXEL stock?

SEC Form 4 filings show no open-market insider buys at Exelixis, Inc. in the last 90 days (9 sells).

Same arena

Related companies in Biotechnology

IONS

Ionis Pharmaceuticals, Inc.

$12.9B

BBIO

BridgeBio Pharma, Inc.

$13.2B

ASND

Ascendis Pharma A/S

$13.7B

AXSM

Axsome Therapeutics, Inc.

$12B

MDGL

Madrigal Pharmaceuticals, Inc.

$11.5B

JAZZ

Jazz Pharmaceuticals plc

$14.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.